Partners

The development of a successful vaccine is a significant undertaking that takes years to achieve. Sabin Vaccine Development is an internationally recognized product development partnership with a common goal – the development of safe, effective vaccines against tropical infections including human hookworm, schistosomiasis, and malaria. Sabin Vaccine Development's esteemed partners include:

Texas Children's Hospital and Baylor College of Medicine
www.bcm.edu
www.texaschildrens.org
Houston, Texas, MD, USA
Texas Children's Hospital and Baylor College of Medicine house the laboratory focused on antigen discovery, process development, formulation and testing, animal testing, and technology transfer to our manufacturing partners.

The George Washington University (GW) - Department of Microbiology, Immunology and Tropical Medicine
www.gwumc.edu/microbiology
Washington, DC, USA
GW is primarily on the preclinical immunological assessment and potency testing of new vaccines. In addition, it investigates the immune response of humans to Sabin's vaccines that are being tested as well as that of natural infection with helminths.

Fundação Oswaldo Cruz (FIOCRUZ)
www.fiocruz.br
Belo Horizonte, Minas Gerais, Brazil
FIOCRUZ serves as the center for epidemiological assessments, clinical testing and the management of a vaccine testing center in rural Brazil, complete with a clinic and field laboratory.

James Cook University (JCU)
www.jcu.edu.au
Brisbane, Queensland, Australia
JCU performs research and development activities primarily for target candidate discovery, early evaluation, characterization and ranking.

London School of Hygiene and Tropical Medicine (LSHTM)
www.lshtm.ac.uk
London, England
LSHTM designs and conducts statistical analysis of the clinical trials in Brazil. They also conduct mathematical modeling and cost-effectiveness analysis which have informed our global access strategy including vaccine development, introduction, distribution and financing.

Instituto Butantan
www.butantan.gov.br
Sao Paulo, Brazil
Insituto Butantan is a public sector vaccine manufacturer in Sao Paulo, Brazil, which produces 80% of the nation’s vaccines. A member of the Developing Country Vaccine Manufacturing Network, Instituto Butantan serves as the Brazilian manufacturing partner for technology transfer, scale-up process development and clinical grade manufacture of the hookworm and schistosomiasis vaccines.

The Institute of Parasite Diseases, Chinese Centers for Disease Control and Prevention
www.chinacdc.net.cn/n272562
Beijing, China
IPD carries out research and training, coordinates the national research program on parasitic diseases, and provides scientific and technical guidance to research centers in China. IPD performs preclinical testing by utilizing a unique model to evaluate the same species of human hookworm that is being targeted by the vaccine, Necator americanus.